DGAP-News: Alphaform AG / Key word(s): Half Year Results Alphaform AG: Interim Report 2nd Quarter 2012 10.08.2012 / 11:28 --------------------------------------------------------------------- Press release First half of year 2012: Upwards trend continues at Alphaform Revenue climbs by 10.1% to EUR14.1 million as against the same period of the previous year Operating result at EUR0.4 million still clearly positive Forecast for the business year 2012 is confirmed Feldkirchen, 10th August 2012 - Alphaform AG, as specialist in additive manufacturing and a leading company in the production of orthopaedic implants and instruments, increased the group revenue in the first half of the year 2012 by 10.1% up to EUR14.1 million compared to the previous year (first half of year 2011: EUR12.8 million). After the net result in the first half of the year 2011 was still at EUR-0.25 million, it rose considerably to positive EUR0.4 million. EBITDA (resulted from interest, taxes and deductions) climbed from EUR0.55 million in the first half of the year 2011 to EUR1.2 million in the same reporting period in 2012. The cash flow from operating activities in the Alphaform Group increased in the first half of the year 2012 to EUR-0.1 million, after EUR-1.0 million in the same period in 2011. The cause for this increase, is the improved operational performance in the whole group. This fact is also reflected on an improved gross profit margin, which climbed by 5.6% up to 71.7% (first half of the year 2011: 66.1%). Alphaform earnings per share amounted to EUR0.07 in the first six months of the year 2012, after EUR-0.05 in the first half of the year 2011. Premium automotive manufacturers bring order boom The still high demand for prototypes caused by developing activities in the automotive industry, specially the new developments in the premium segment, as well as electric cars, provides for high revenues in the business areas Rapid Prototyping and Rapid Tooling since already the second quarter of 2011. Although the economical situation in the automotive industry is generally decreasing, premium automotive manufacturers still reached good results and they confirmed the strategy of the technology and model offensive. For this, Alphaform still expects constant revenues in this area. Medical technology with significantly improved results In the medical technology business area, revenues slightly rose again in the second quarter of 2012, after they reduced considerably in the first quarter compared to the previous year. Implants post processing, which usually have been subcontracted, were insourced at the beginning of the year by the customer himself. This insourcing was reasonable for the revenues reduction. The on-going enhancement measures program reached further costs savings, so that the revenue margin climbed to 3% in the second quarter. Since July, a casting specialist with restructuring experience is leading the subsidiary MediMet. The previous manager director and founder of MediMet remains at our side as advisor. We want to raise the revenue marge to 10% until the business year 2014. The order situation and customer relations keep intact, so that Alphaform can count on a constant development of the medical technology area, and the goal of a sustainable results improvement will be reached in this year. The development of the foreign subsidiaries in Scandinavia and the UK also continues being positive. In the first half of the year 2012, a profitable growth of 20.7% in Scandinavia and 67.7% in the UK could be reached in all the activities, compared to the period of the previous year. The Claho subsidiary is operating at good capacity, the same as in the previous year. Forecast for the business year 2012 is confirmed Alphaform expects for the rest of the business year 2012 stable revenues at the same level of the previous year. Prototyping business probably might continue taking advantage of the intensive developing activity in the premium automotive sector. A constant market development is expected in the medical implants and instruments area, in which revenues and customer base largely remain the same. Positive drive results from the enhancement measures program in the medical technology and from the improved product mix in prototyping. For the complete year 2012, Alphaform AG forecasts a slightly higher revenue compared to the previous year and a positive consolidated net result as well, as far as the targeted industries of the company continue developing positive - considering the worldwide uncertain economic situation. Key figures of the Alphaform Group |[![CDATA[|[pre|]]]|] EURm 1st half year 2012 2011 Change Revenues 14.083 12.790 10.1 % EBITDA 1.161 0.549 111.5% EBIT 0.508 -0.095 - Earnings after taxes 0.387 -0.248 - Earnings per share 0.07 EUR -0.05 EUR - Equity as of 30 June (2011: 31 Dec) 12.631 12.254 3.1 % Balance sheet total as of 30 June 20.485 20.491 0.0 % (2011: 31 Dec) Equity ratio (percent) 61.7 % 59.8 % 3.1 % Free liquidity as of 30 June (2011: 1.142 1.883 -39.4% 31 Dec) Employees Group as of 30 June (2011: 231 239 -3.3 % 31 Dec) |[![CDATA[|[/pre|]]]|] About Alphaform Alphaform AG, based in Feldkirchen near Munich and founded in 1996, is a production company for complex components and products produced in smaller batches. Alphaform is among the European market leaders in prototyping, the production of near-series prototypes, particularly for the automotive and capital goods industries. The company has a leading position throughout Europe in the manufacturing of orthopaedic implants and instruments. Alphaform's shares are listed in the Prime Standard segment of the Frankfurt stock exchange (code: ATF). The core competence of Alphaform lies in its extensive application expertise for processes and materials for the additive production of complex prototypes, tools, individual components and small series of plastics and metals. The company's work focuses on the orthopaedic and medical technology, automotive, aviation and aerospace industries. There are Alphaform subsidiaries in Germany, Finland, Sweden and the UK. Contact: Dr. Thomas Vetter CEO ALPHAFORM AG KapellenstraÃe 10 85622 Feldkirchen Tel.: +49 89 905002 21 Fax: +49 89 9050021021e-mail: tvetter@alphaform.de Internet: www.alphaform.de End of Corporate News --------------------------------------------------------------------- 10.08.2012 Dissemination of a Corporate News, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- Language: English Company: Alphaform AG KapellenstraÃe 10 85622 Feldkirchen Germany Phone: +49 (0)89 905002 - 0 Fax: +49 (0)89 905002 - 90 E-mail: ir@alphaform.de Internet: www.alphaform.de ISIN: DE0005487953 WKN: 548795 Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, München, Stuttgart End of News DGAP News-Service --------------------------------------------------------------------- 181269 10.08.2012
DGAP-News: Alphaform AG: Interim Report 2nd Quarter 2012
| Source: EQS Group AG